Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Breast 1

Conditions

Mesothelioma 3Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Thymoma 1Pancreatic Neoplasms 1Neoplasms 1Mesothelioma, Malignant 1Cholangiocarcinoma 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 12Nivolumab 4fludarabine 3Gemcitabine 3Drug Therapy 3Cisplatin 3spartalizumab 2budigalimab 2Injections 2Fluorodeoxyglucose F18 2Cyclophosphamide 2zenocutuzumab 1venetoclax 1ulixertinib 1tocilizumab 1tislelizumab 1seribantumab 1saracatinib 1rovalpituzumab tesirine 1pertuzumab 1pemigatinib 1niraparib 1neratinib 1milademetan 1margetuximab 1erdafitinib 1entrectinib 1cobimetinib 1cediranib 1bemarituzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cholangiocarcinoma × anetumab ravtansine × Thoracic × Clear all
NCT03102320 2022-06-30

ARCS-Multi

Bayer

Phase 1 Completed
173 enrolled
BreastGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Pancreatic Neoplasms, Thymoma, Cholangiocarcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡